R4D’s Market Dynamics Practice harnesses the power of the private sector to broaden access to vital goods that positively impact the lives of hundreds of millions globally. R4D has developed strategies to achieve over a billion dollars in efficiency savings and ensure sustainable availability of high-quality products for nutrition, AIDS, malaria, and neglected diseases treatment and prevention. Read more...
The field of Market Dynamics is a relatively nascent one, having arisen in the last few decades in response to recognition of opportunities to address public and private sector markets that fail to optimize access to critical global health commodities such as diagnostics or treatments—these products can languish for years without reaching their intended recipients.
Globally, malaria is still responsible for nearly 700,000 unnecessary deaths per year. Long-lasting insecticide-treated bed nets (LLINs) or “nets” have been instrumental in reversing that trend and have contributed to a 25% decline in malaria-related deaths over the past decade.
Diarrheal disease, which is primarily caused by lack of access to adequate sanitation and safe drinking water, is the second biggest killer of children under five years of age globally. Approximately 2.5 billion people live without access to safe sanitation facilities.
In 2012, Market Dynamics Managing Director Kanika Bahl served as co-chair of the Market Shaping Working Group of the UN Commission on Life-Saving Commodities for Women and Children, with the R4D team shaping recommendations for this group.
In July 2011, the Bill and Melinda Gates Foundation commissioned R4D to identify opportunities to improve the global marketplace for LLINs. R4D rapidly engaged with 70 actors including suppliers, countries, and global financiers and regulators to achieve this.
Starting in September 2011, with support from the Bill and Melinda Gates Foundation, R4D has been working to increase global PZQ production and developing a set of medium-term market strategies focused on achieving sustainable pricing levels, ensuring high-quality production.
In February 2011, the Global Fund’s Market Dynamics Committee (MDC) commissioned R4D to develop concrete strategies which optimized ‘value for money’ across its health commodities portfolio, with a particular focus on HIV/AIDS drugs.